SCHEMBL29426941

SCHEMBL29426941

CCc1nc(OC2CCC3(CC2)CN(C(=O)OC(C)(C)C)C3)ccc1C(F)F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 6/20 0.40
▸ DGAT1 O75907 1/20 0.38
▸ PDE4D Q08499 4/20 0.37
▸ CACNB4 O00305 1/20 0.37
▸ CACNA1A O00555 1/20 0.37
▸ CACNA1G O43497 1/20 0.37
▸ CACNG3 O60359 1/20 0.37
▸ CACNA1F O60840 1/20 0.37
▸ CACNA1H O95180 1/20 0.37
▸ CACNB3 P54284 1/20 0.37
▸ CACNA2D1 P54289 1/20 0.37
▸ CACNG7 P62955 1/20 0.37
▸ CACNA1B Q00975 1/20 0.37
▸ CACNA1D Q01668 1/20 0.37
▸ CACNB1 Q02641 1/20 0.37
▸ CACNG1 Q06432 1/20 0.37
▸ CACNB2 Q08289 1/20 0.37
▸ CACNA1S Q13698 1/20 0.37
▸ CACNA1C Q13936 1/20 0.37
▸ CACNA1E Q15878 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26631383 1.00 GPR119 (0.40) GPR119DGAT1PDE4DCACNB4CACNA1A
SCHEMBL25411482 0.88 GPR119 (0.42) GPR119DGAT1PDE4DPDE4APDE4B
SCHEMBL25434328 0.88 ACACB (0.34) DGAT1ACACB
SCHEMBL26631373 0.86 GPR119 (0.41) GPR119DGAT1PDE4DCACNB4CACNA1A
SCHEMBL29426971 0.84 GPR119 (0.40) GPR119DGAT1PDE4DPDE4APDE4B
SCHEMBL26631457 0.84 GPR119 (0.40) GPR119DGAT1PDE4DPDE4APDE4B
SCHEMBL29427106 0.83 PDE4D (0.37) GPR119PDE4DRORCPDE4APDE4B
SCHEMBL25412820 0.83 PDE4D (0.37) GPR119PDE4DRORCPDE4APDE4B
SCHEMBL29426752 0.83 CHRM4 (0.34) ACACB
SCHEMBL26631081 0.83 CHRM4 (0.34) ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4217062-B1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-10-09 — — EP disclosed
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-06-27 — — US disclosed
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2023-10-31 — — US disclosed
EP-4217062-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN Pharmaceutica NV (BE) 2023-08-02 — — EP disclosed
WO-2022063784-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-31 — — WO disclosed
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-03-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208902-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP GPR119 216/4885DGAT1 70/4885PDE4D 765/4885
US-20220089538-A1 CYCLOBUTYL AMIDE MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP GPR119 217/4885DGAT1 67/4885PDE4D 738/4885
US-11802111-B2 Cyclobutyl amide monoacylglycerol lipase modulators MGLL, LPL, PNLIP GPR119 217/4885DGAT1 67/4885PDE4D 738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback